Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garsorasib combination therapy in KRAS G12C-mutated NSCLC
NCT05492045Phase 2Terminated
- Sponsor
- InventisBio
- Start
- Sep 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of garsorasib in non-small cell lung cancer (NSCLC), sponsored by InventisBio. Started Sep 2022; status: terminated.
02
Drugs
garsorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05492045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05492045.